Neuralstem Updates ALS Clinical Trial Progress

The Safety Review Board has reviewed health data from the first six ALS patients participating in Neuralstem’s stem cell trial and has approved advancing to the next group of ALS patients. While enrollment was restricted to non-ambulatory patients in the first group undergoing treatment, the second group will include ambulatory patients at an earlier stage of disease progression.

Click here to read more.

Share this: